Forte Biosciences, Inc. Common Stock (FBRX)

Price$16.52

Value ScoreF

Growth ScoreF

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-18.92%

Price vs S&P 500 (4W)-31.21%

VGM Score21.60

Market Capitalization$338.31M

All Metrics

Book Value / Share (Quarterly)$3.03

P/TBV (Annual)0.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-7.17%

Cash Flow / Share (Quarterly)$-4.27

Price vs S&P 500 (YTD)-47.58%

Net Profit Margin (TTM)-158775.00%

EPS (TTM)$-4.58

10-Day Avg Trading Volume0.28M

EPS Excl Extra (TTM)$-4.58

Revenue Growth (5Y)-7.79%

EPS (Annual)$-4.71

ROI (Annual)-113.75%

Net Profit Margin (5Y Avg)-73895.28%

Cash / Share (Quarterly)$4.19

Revenue Growth QoQ (YoY)0.00%

ROA (Last FY)-83.81%

Revenue Growth TTM (YoY)-99.78%

EBITD / Share (TTM)$-4.72

ROE (5Y Avg)-71.71%

Operating Margin (TTM)-150175.00%

Cash Flow / Share (Annual)$-3.94

P/B Ratio8.04x

P/B Ratio (Quarterly)8.54x

Net Income / Employee (Annual)$-3,651,300

EV / Revenue (TTM)7002.18x

Net Interest Coverage (TTM)-27.11x

ROA (TTM)-85.50%

EPS Incl Extra (Annual)$-4.71

Current Ratio (Annual)3.88x

Quick Ratio (Quarterly)2.50x

3-Month Avg Trading Volume0.27M

52-Week Price Return59.61%

Revenue / Employee (TTM)$2,100

Tangible BV / Share (Quarterly)$1.11

P/S Ratio (Annual)8457.75x

Asset Turnover (Annual)0.00x

52-Week High$35.80

Operating Margin (5Y Avg)-70736.83%

EPS Excl Extra (Annual)$-4.71

CapEx CAGR (5Y)-38.77%

Tangible BV CAGR (5Y)-11.40%

26-Week Price Return-10.99%

Quick Ratio (Annual)3.77x

13-Week Price Return-45.44%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.75x

Enterprise Value$280.09M

Revenue / Share Growth (5Y)-12.31%

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)0.47%

Revenue / Employee (Annual)$2,100

Pretax Margin (Annual)-158800.00%

Cash / Share (Annual)$5.94

3-Month Return Std Dev93.56%

Net Income / Employee (TTM)$-3,992,400

ROE (Last FY)-113.75%

Net Interest Coverage (Annual)-27.23x

EPS Basic Excl Extra (Annual)$-4.71

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-4.58

ROI (TTM)-106.16%

P/S Ratio (TTM)8457.75x

Pretax Margin (5Y Avg)-73893.39%

Revenue / Share (Annual)$0.03

Tangible BV / Share (Annual)$1.85

Price vs S&P 500 (52W)35.25%

Year-to-Date Return-39.42%

5-Day Price Return-14.14%

EPS Normalized (Annual)$-4.71

ROA (5Y Avg)-61.08%

Net Profit Margin (Annual)-158800.00%

Month-to-Date Return-13.37%

Cash Flow / Share (TTM)$-0.86

EBITD / Share (Annual)$-4.80

Operating Margin (Annual)-150175.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-71.71%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-4.58

P/TBV (Quarterly)0.41x

P/B Ratio (Annual)5.60x

Pretax Margin (TTM)-158775.00%

Book Value / Share (Annual)$4.71

Price vs S&P 500 (13W)-53.70%

Beta2.94x

Revenue / Share (TTM)$0.03

ROE (TTM)-106.16%

52-Week Low$9.10

vGradeF

gGradeF

mGradeD

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-1.24est. -1.22

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.17

4.18

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
FBRXForte Biosciences, Inc. Common Stock	F	F	D	$16.52
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Forte Biosciences is a biopharmaceutical company developing FB-102, a proprietary therapeutic molecule targeting autoimmune and inflammatory disorders. The candidate is in preclinical trials with potential applications in graft-versus-host disease, vitiligo, alopecia areata, and type 1 diabetes.